Results 51 to 60 of about 20,028 (211)
Frontiers in PharmacologyProprotein convertase subtilisin/kexin type 9 (PCSK9) is primarily secreted by hepatocytes. PCSK9 is critical in liver low-density lipoprotein receptors (LDLRs) metabolism.
Fengyuan Lu +3 more
doaj +1 more source
PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation
Mediators of Inflammation, 2020 Epicardial adipose tissue (EAT) has the unique property to release mediators that nourish the heart in healthy conditions, an effect that becomes detrimental when volume expands and proinflammatory cytokines start to be produced.
Elena Dozio +7 more
doaj +1 more source
Insight into the Evolving Role of PCSK9
Metabolites, 2022 Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the last discovered member of the family of proprotein convertases (PCs), mainly synthetized in hepatic cells. This serine protease plays a pivotal role in the reduction of the number of low-density lipoprotein receptors (LDLRs) on the surface of hepatocytes, which leads to an increase in the ...
Mateusz Maligłówka +9 more
openaire +4 more sources
Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice
Frontiers in PharmacologyInstructionAccumulating evidence has shown that proprotein convertase subtilisin/kexin type 9 (PCSK9) is associated with inflammation in the vascular system. However, the roles of PCSK9 in hepatic inflammation remain unclear.
Xue-Ying Zhang +6 more
doaj +1 more source
The Role of PCSK9 in Infectious Diseases
Current Medicinal Chemistry, 2022 Background: In recent years, many aspects of the physiological role of PCSK9 have been elucidated, in particular regarding its role in lipid metabolism, cardiovascular risk but also its role in innate immunity. Increasing evidence is available on the involvement of PCSK9 in the pathogenesis of viral infections, mainly HCV, as well as in the regulation
Magnasco, Laura +7 more
openaire +3 more sources
PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
Frontiers in Cardiovascular Medicine, 2021 The relevance of PCSK9 in atherosclerosis progression is demonstrated by the benefits observed in patients that have followed PCSK9-targeted therapies.
Aureli Luquero +5 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu +7 more
wiley +1 more source
Serum sdLDL-C and cellular SREBP2-dependent cholesterol levels: Is there a challenge on targeting PCSK9? [PDF]
Journal of Medical Biochemistry, 2016 Background: Serum small dense LDL-cholesterol (sdLDLC) value is suggested to be an important risk factor for atherosclerosis. Since sdLDL-C changes may be related to PCSK9 and SREBP-2 functions, the aim of this study was to investigate correlations ...
Soltanmohammadi Elham +6 more
doaj
Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain. [PDF]
PLoS ONE, 2016 PCSK9 is a secreted ligand and negative post-translational regulator of low-density lipoprotein receptor (LDLR) in hepatocytes. Gain-of-function (GOF) or loss-of-function (LOF) mutations in PCSK9 are directly correlated with high or low plasma LDL ...
Steve Poirier +4 more
doaj +1 more source
Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
Metabolites, 2022 In adults, elevated levels of circulating Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) have been associated with increased Low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and worse cardiovascular outcomes.
Yara Azar +11 more
doaj +1 more source